Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

BACKGROUND: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Br J Cancer
मुख्य लेखकों: Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341887/
https://ncbi.nlm.nih.gov/pubmed/32346071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0845-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन